MLMartin Lecomte

Martin Lecomte

*This is an algorithmically generated author record based on publicly available information.

Martin Lecomte has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Elodie Bole-Richard

    INSERM UMR1098 RIGHT Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besancon, Franche-Comté, France

    1 shared publication
  • Francine Garnache

    INSERM UMR1098 RIGHT Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besancon, Franche-Comté, France

    1 shared publication
  • François Anna

    Preclinical Department, Invectys, Paris, France

    1 shared publication
  • Jean-Marie Certoux

    INSERM UMR1098 RIGHT Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besancon, Franche-Comté, France

    1 shared publication
  • Joel LeMaoult

    Service de Recherche en Hémato-Immunologie (SRHI), CEA, Paris, France

    1 shared publication
  • Julien Caumartin

    Preclinical Department, Invectys, Paris, France. 7

    1 shared publication

Latest Publications

  • Open Access

    First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G

    by François Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Marie Certoux, Philippe Souque, Francine Garnache, Olivier Adotevi, Pierre Langlade-Demoyen, et al.

    Background: CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microenvironment sometimes caused by the tumorous expression of immune checkpoints (ICPs) such as HLA-G. Indeed, HLA-G is remarkable because it is both a potent ICP and a TSA. HLA-G tumor expression causes immune escape by impairing innate and adaptive immune responses and by inducing a suppressive microenvironment. Yet, to date, no immunotherapy targets it. Methods: We have developed two anti-HLA-G third-generation CARs based on new anti-HLA-G monoclonal antibodies. Results: Anti-HLA-G CAR-T cells were specific for immunosuppressive HLA-G isoforms. HLA-G-activated CAR-T cells polarized toward T helper 1, and became cytotoxic against HLA-G+ tumor cells. In vivo, anti-HLA-G CAR-T cells were able to control and eliminate HLA-G+ tumor cells. The interaction of tumor-HLA-G with interleukin (IL)T2-expressing T cells is known to result in effector T cell functional inhibition, but anti-HLA-G CAR-T cells were insensitive to this inhibition and still exerted their function even when expressing ILT2. Lastly, we show that anti-HLA-G CAR-T cells differentiated into long-term memory effector cells, and seemed not to lose function even after repeated stimulation by HLA-G-expressing tumor cells. Conclusion: We report for the first time that HLA-G, which is both a TSA and an ICP, constitutes a valid target for CAR-T cell therapy to specifically target and eliminate both tumor cells and HLA-G+ suppressive cells.